Detailed description page of THPdb

This page displays user query in tabular form.

Th1111 details

Primary information
ID 1532
ThPP ID Th1111
Therapeutic Peptide/Protein Name Defibrotide
Sequence DNA (sodium Salt) view full sequnce in fasta
Functional Classification N.A.
Molecular Weight N.A.
Chemical Formula N.A.
Isoelectric Point N.A.
Hydrophobicity N.A.
Melting Point (℃) N.A.
Half Life t1/2-alpha = minutes (10-20 minutes in rat); t1/2-beta = a few hours
Description Sodium salt of a mixture of single-stranded oligodeoxyribonucleotides, derived from porcine mucosal DNA. It has been shown to possess antithrombotic, anti-inflammatory and anti-ischemic properties and without the associated disadvantages of significant systemic anticoagulant effects. It is marketed under the brand names Dasovas (FM), Noravid, and Prociclide in a variety of countries, but is currently not approved in the USA. The manufacturer is Gentium.
Indication/Disease Defibrotide is used to treat or prevent a failure of normal blood flow (occlusive venous disease, OVD) in the liver of patients who have had bone marrow transplants or received certain drugs such as oral estrogens, mercaptopurine, and many others
Pharmacodynamics Defibrotide is a deoxyribonucleic acid derivative extracted from mammalian organs, which has been developed for the treatment of a number of vascular disorders. It appears to increase fibrinolysis and may possess antithrombotic, antiatherosclerotic and anti-ischaemic actions, probably due to its ability to selectively increase prostaglandin I2 and E2 levels and to increase tissue plasminogen activator and decrease plasminogen activator inhibitor function. Defibrotide is available as an intravenous and intramuscular preparation, and also as an oral formulation for long term use.
Mechanism of Action The drug appears to prevent the formation of blood clots and to help dissolve blood clots by increasing levels of prostaglandin I2, E2, and prostacyclin, altering platelet activity, increasing tissue plasminogen activator function, and decreasing activity of tissue plasminogen activator inhibitor. Prostaglandin I2 relaxes the smooth muscle of blood vessels and prevents platelets from adhering to each other. Prostaglandin E2 at certain concentrations also inhibits platelet aggregation. Moreover, the drug provides additional beneficial anti-inflammatory and antiischemic activities as recent sudies have shown. It is yet unclear, if the latter effects can be utilized clinically (e.g., treatment of ischemic stroke).
Toxicity N.A.
Metabolism N.A.
Absorption Bioavailability is 58-70% following oral administration, compared to parenteral forms (i.v. and i.m. = 100%).
Volume of Distribution N.A.
Clearance N.A.
Categories Antithrombins
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target Adenosine receptor A1,Adenosine receptor A2a,Adenosine receptor A2b
Information of corresponding available drug in the market
Brand Name Noravid
Company sanofi-aventis
Brand Discription Defibrotide is the sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA. It has been shown to have antithrombotic, anti-inflammatory and anti-ischemic properties (but without associated significant systemic anticoagulant effects). It is marketed under the brand names Dasovas (FM), Noravid, and Prociclide in a variety of countries, but is currently not approved in the USA. The drug appears to prevent the formation of blood clots and to help dissolve blood clots by increasing levels of prostaglandin I2, E2, and prostacyclin, altering platelet activity, increasing tissue plasminogen activator function, and decreasing activity of tissue plasminogen activator inhibitor. Prostaglandin I2 relaxes the smooth muscle of blood vessels and prevents platelets from adhering to each other. Prostaglandin E2 at certain concentrations also inhibits platelet aggregation. Moreover, the drug provides additional beneficial anti-inflammatory and antiischemic activities as recent sudies have shown. It is yet unclear, if the latter effects can be utilized clinically (e.g., treatment of ischemic stroke).
Prescribed for Defibrotide is used to treat or prevent a failure of normal blood flow (occlusive venous disease, OVD) in the liver of patients who have had bone marrow transplants or received certain drugs such as oral estrogens, mercaptopurine, and many others.
Chemical Name Polydeoxyribonucleotides of bovine lung
Formulation N. A.
Physcial Appearance N. A.
Route of Administration N.A.
Recommended Dosage 6.25mg/kg body weight every 6 hours (25mg/kg/day)
Contraindication N.A.
Side Effects N.A.
Useful Link http://drug-info.in/noravid-defibrotide-sanofi-aventis/ http://www.pharmgkb.org/drug/PA164749105#tabview=tab1&subtab=31 https://duckduckgo.com/l/?kh=-1&uddg=http%3A%2F%2Fwww.fda.gov%2Fohrms%2Fdockets%2Fac%2F07%2Fslides%2F2007-4316s1-01-FDA-Shashaty.ppt
PubMed ID 3754833, 17495522, 16584299, 8807733, 8511753, 7681375
3-D Structure N.A.

OSDDlinux

Raghava's Group

IMTECH

CSIR

CRDD
CPPSITE 2.0

Primary information
ID	1532
ThPP ID	Th1111
Therapeutic Peptide/Protein Name	Defibrotide
Sequence	DNA (sodium Salt) view full sequnce in fasta
Functional Classification	N.A.
Molecular Weight	N.A.
Chemical Formula	N.A.
Isoelectric Point	N.A.
Hydrophobicity	N.A.
Melting Point (℃)	N.A.
Half Life	t1/2-alpha = minutes (10-20 minutes in rat); t1/2-beta = a few hours
Description	Sodium salt of a mixture of single-stranded oligodeoxyribonucleotides, derived from porcine mucosal DNA. It has been shown to possess antithrombotic, anti-inflammatory and anti-ischemic properties and without the associated disadvantages of significant systemic anticoagulant effects. It is marketed under the brand names Dasovas (FM), Noravid, and Prociclide in a variety of countries, but is currently not approved in the USA. The manufacturer is Gentium.
Indication/Disease	Defibrotide is used to treat or prevent a failure of normal blood flow (occlusive venous disease, OVD) in the liver of patients who have had bone marrow transplants or received certain drugs such as oral estrogens, mercaptopurine, and many others
Pharmacodynamics	Defibrotide is a deoxyribonucleic acid derivative extracted from mammalian organs, which has been developed for the treatment of a number of vascular disorders. It appears to increase fibrinolysis and may possess antithrombotic, antiatherosclerotic and anti-ischaemic actions, probably due to its ability to selectively increase prostaglandin I2 and E2 levels and to increase tissue plasminogen activator and decrease plasminogen activator inhibitor function. Defibrotide is available as an intravenous and intramuscular preparation, and also as an oral formulation for long term use.
Mechanism of Action	The drug appears to prevent the formation of blood clots and to help dissolve blood clots by increasing levels of prostaglandin I2, E2, and prostacyclin, altering platelet activity, increasing tissue plasminogen activator function, and decreasing activity of tissue plasminogen activator inhibitor. Prostaglandin I2 relaxes the smooth muscle of blood vessels and prevents platelets from adhering to each other. Prostaglandin E2 at certain concentrations also inhibits platelet aggregation. Moreover, the drug provides additional beneficial anti-inflammatory and antiischemic activities as recent sudies have shown. It is yet unclear, if the latter effects can be utilized clinically (e.g., treatment of ischemic stroke).
Toxicity	N.A.
Metabolism	N.A.
Absorption	Bioavailability is 58-70% following oral administration, compared to parenteral forms (i.v. and i.m. = 100%).
Volume of Distribution	N.A.
Clearance	N.A.
Categories	Antithrombins
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	Adenosine receptor A1,Adenosine receptor A2a,Adenosine receptor A2b
Information of corresponding available drug in the market
Brand Name	Noravid
Company	sanofi-aventis
Brand Discription	Defibrotide is the sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA. It has been shown to have antithrombotic, anti-inflammatory and anti-ischemic properties (but without associated significant systemic anticoagulant effects). It is marketed under the brand names Dasovas (FM), Noravid, and Prociclide in a variety of countries, but is currently not approved in the USA. The drug appears to prevent the formation of blood clots and to help dissolve blood clots by increasing levels of prostaglandin I2, E2, and prostacyclin, altering platelet activity, increasing tissue plasminogen activator function, and decreasing activity of tissue plasminogen activator inhibitor. Prostaglandin I2 relaxes the smooth muscle of blood vessels and prevents platelets from adhering to each other. Prostaglandin E2 at certain concentrations also inhibits platelet aggregation. Moreover, the drug provides additional beneficial anti-inflammatory and antiischemic activities as recent sudies have shown. It is yet unclear, if the latter effects can be utilized clinically (e.g., treatment of ischemic stroke).
Prescribed for	Defibrotide is used to treat or prevent a failure of normal blood flow (occlusive venous disease, OVD) in the liver of patients who have had bone marrow transplants or received certain drugs such as oral estrogens, mercaptopurine, and many others.
Chemical Name	Polydeoxyribonucleotides of bovine lung
Formulation	N. A.
Physcial Appearance	N. A.
Route of Administration	N.A.
Recommended Dosage	6.25mg/kg body weight every 6 hours (25mg/kg/day)
Contraindication	N.A.
Side Effects	N.A.
Useful Link	http://drug-info.in/noravid-defibrotide-sanofi-aventis/ http://www.pharmgkb.org/drug/PA164749105#tabview=tab1&subtab=31 https://duckduckgo.com/l/?kh=-1&uddg=http%3A%2F%2Fwww.fda.gov%2Fohrms%2Fdockets%2Fac%2F07%2Fslides%2F2007-4316s1-01-FDA-Shashaty.ppt
PubMed ID	3754833, 17495522, 16584299, 8807733, 8511753, 7681375
3-D Structure	N.A.

Updated version of this database is available at ThpDB2

Detailed description page of THPdb